Chengdu Easton Biopharmaceuticals Co., Ltd. (SHA:688513)
China
· Delayed Price · Currency is CNY 57.21
-0.74 (-1.28%)
Mar 9, 2026, 3:00 PM CST
SHA:688513 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 1,331 | 1,348 | 1,116 | 1,170 | 1,023 | Upgrade
|
| Other Revenue | - | 1.84 | 1.42 | 0.63 | 0.07 | Upgrade
|
| Revenue | 1,331 | 1,350 | 1,117 | 1,171 | 1,023 | Upgrade
|
| Revenue Growth (YoY) | -1.36% | 20.82% | -4.56% | 14.43% | 10.96% | Upgrade
|
| Cost of Revenue | - | 345.23 | 226.94 | 199.11 | 146.32 | Upgrade
|
| Gross Profit | 1,331 | 1,005 | 890.18 | 971.4 | 876.62 | Upgrade
|
| Selling, General & Admin | - | 552.93 | 483.43 | 564.44 | 528.06 | Upgrade
|
| Research & Development | - | 262.77 | 237.45 | 229.99 | 199.59 | Upgrade
|
| Other Operating Expenses | 1,019 | 17.37 | 17.46 | 18.15 | 15.75 | Upgrade
|
| Operating Expenses | 1,019 | 836.11 | 737.98 | 814 | 741.14 | Upgrade
|
| Operating Income | 312.52 | 168.42 | 152.2 | 157.4 | 135.47 | Upgrade
|
| Interest Expense | - | -3.68 | -3.42 | -2.61 | -0.36 | Upgrade
|
| Interest & Investment Income | - | 27.38 | 25.61 | 20.69 | 32.83 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 0.16 | 0 | 0.03 | 0.02 | Upgrade
|
| Other Non Operating Income (Expenses) | -13.14 | 0.28 | -0.1 | -0.11 | -0.19 | Upgrade
|
| EBT Excluding Unusual Items | 299.38 | 192.56 | 174.29 | 175.41 | 167.77 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | 14.92 | 14.57 | 19.99 | 13.69 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | -0.11 | 0.03 | 0.19 | -0.1 | Upgrade
|
| Other Unusual Items | - | 45.22 | 52.76 | 66.4 | 65.56 | Upgrade
|
| Pretax Income | 299.38 | 252.59 | 241.64 | 261.99 | 246.92 | Upgrade
|
| Income Tax Expense | 16.13 | 14.35 | 15.07 | 15.47 | 14.49 | Upgrade
|
| Net Income | 283.25 | 238.23 | 226.57 | 246.52 | 232.43 | Upgrade
|
| Net Income to Common | 283.25 | 238.23 | 226.57 | 246.52 | 232.43 | Upgrade
|
| Net Income Growth | 18.89% | 5.15% | -8.09% | 6.06% | 30.46% | Upgrade
|
| Shares Outstanding (Basic) | 174 | 175 | 177 | 177 | 176 | Upgrade
|
| Shares Outstanding (Diluted) | 174 | 175 | 177 | 177 | 176 | Upgrade
|
| Shares Change (YoY) | -0.80% | -1.04% | 0.14% | 0.37% | 19.70% | Upgrade
|
| EPS (Basic) | 1.63 | 1.36 | 1.28 | 1.39 | 1.32 | Upgrade
|
| EPS (Diluted) | 1.63 | 1.36 | 1.28 | 1.39 | 1.32 | Upgrade
|
| EPS Growth | 19.85% | 6.25% | -8.22% | 5.68% | 8.98% | Upgrade
|
| Free Cash Flow | - | 145.82 | 99.99 | -187.38 | -122.59 | Upgrade
|
| Free Cash Flow Per Share | - | 0.83 | 0.56 | -1.06 | -0.70 | Upgrade
|
| Dividend Per Share | - | 0.430 | 0.395 | 0.381 | 0.531 | Upgrade
|
| Dividend Growth | - | 8.97% | 3.57% | -28.19% | 159.97% | Upgrade
|
| Gross Margin | 100.00% | 74.42% | 79.68% | 82.99% | 85.70% | Upgrade
|
| Operating Margin | 23.47% | 12.48% | 13.62% | 13.45% | 13.24% | Upgrade
|
| Profit Margin | 21.27% | 17.65% | 20.28% | 21.06% | 22.72% | Upgrade
|
| Free Cash Flow Margin | - | 10.80% | 8.95% | -16.01% | -11.98% | Upgrade
|
| EBITDA | 393.89 | 249.79 | 225.43 | 215.75 | 168.08 | Upgrade
|
| EBITDA Margin | 29.59% | 18.51% | 20.18% | 18.43% | 16.43% | Upgrade
|
| D&A For EBITDA | 81.37 | 81.37 | 73.23 | 58.35 | 32.6 | Upgrade
|
| EBIT | 312.52 | 168.42 | 152.2 | 157.4 | 135.47 | Upgrade
|
| EBIT Margin | 23.47% | 12.48% | 13.62% | 13.45% | 13.24% | Upgrade
|
| Effective Tax Rate | 5.39% | 5.68% | 6.24% | 5.90% | 5.87% | Upgrade
|
| Revenue as Reported | - | 1,350 | 1,117 | 1,171 | 1,023 | Upgrade
|
| Advertising Expenses | - | - | - | 403 | 393.56 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.